CD8A and neoplasm: This soluble SA-4-1BBL has shown potent immune activity as an adjuvant component of TAA-based vaccines by targeting various cells of innate, such as DCs and NK cells, and adaptive, such as CD4+ and CD8+ T cells, immunity in various preclinical tumor models [5]–[7], [9].